Naloxone Nasal Spray Co-Prescription for the Prevention of Opioid Overdose Complications by Raju, Princy












College of Nursing, East Carolina University 
Doctor of Nursing Practice 
Dr. Courtney Caiola 
04/24/2021 
NALOXONE NASAL SPRAY COPRESCRIPTION 2 
 
Acknowledgments 
First and foremost, I would like to thank God almighty for keeping me safe and guiding 
me throughout my life. I don’t have enough words to express my gratitude towards my DNP 
faculty at East Carolina University, Dr. Skipper the director of the DNP program, Dr Tillman, 
DNP project director and Dr Courtney Caiola, my DNP project coach and mentor and all other 
faculty members who supported and guided us through the most difficult period of our academic 
journey in the midst of a pandemic. I would also like to thank all my fellow classmates who 
supported and encouraged each other, with words and deeds. My sincere thanks go to my family, 
my Husband Raju Pappachan and children Jerril, Irine, and Ashlyn for staying with  
me during the peaks and valleys of this academic journey.  
  
NALOXONE NASAL SPRAY COPRESCRIPTION 3 
 
Dedication 
It is with deepest gratitude and utmost love that I dedicate this project to my family.  I 
give special thanks to my husband Raju Pappachan, who accepted my frustrations and 
celebrations equally, calmly and encouraged me constantly. My family far and near, played a 
significant role in my success with prayers, love, and support. This DNP project took a great 
amount of time and energy, which otherwise I could have spent with my children. I thank my 
children for the unconditional love and understanding they provided me throughout the course. 
My accomplishment today, the dream of my life, got realistic because of you all.   
  
NALOXONE NASAL SPRAY COPRESCRIPTION 4 
 
Abstract 
Background: Opioid overdose is becoming a global epidemic. According to Centers for Disease 
Control and Prevention (CDC), 67,367 drug overdose deaths occurred in the United States (US) 
in 2018. The US Food and Drug Administration (FDA) approved Naloxone nasal spray as a life 
saving measure to reverse the effect of narcotic overdose in community settings. 
Purpose: The purpose of this Doctor of Nursing Practice (DNP) project was to implement an 
educational intervention to increase Naloxone spray co-prescription, at least by 5% during a two 
months period, in a primary care setting. 
Methods: An educational intervention was conducted to teach providers and staff regarding the 
implications of Naloxone nasal sprays in narcotic overdoses and to encourage co-prescriptions of 
Naloxone. Pre and post questionnaire were given to measure the effectiveness of education. The 
IOWA Model of Evidence- Based Practice Implementation was used as the implementation 
framework and chart reviews were used to track the number of narcotic and Naloxone 
prescriptions. 
Results: The findings revealed increased motivation, awareness, confidence, and knowledge 
with Naloxone co-prescription. The chart audit showed that out of 27 narcotic prescriptions 
during an eight-week period, 24 Naloxone prescriptions were written, which is 89% of 
compliance in co-prescription. 
Implications for Practice: The findings of this DNP project indicate that the co-prescription of 
Naloxone can be promoted by educating providers on the significance of the intervention, 
thereby increasing the safety of the patients, reducing health care expenses, and upholding 
nursing values. 
Key words: Narcotic overdose, Naloxone nasal spray, co-prescription, provider 
education, community setting 
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Section I.  Introduction 
Background  
 Narcotic overdose-related complications and deaths are significantly increasing all over 
the world. According to the World Health Organization (WHO), about 275 million people 
worldwide used illicit drugs at least once during 2016 (World Health Organization 
[WHO],2020). The United States of America (USA) reported 67,367, drug overdose deaths in 
2018 (Centers for Disease Control [CDC], 2020). More than 12,000 North Carolina (NC) 
residents died from opioid overdoses from 1999 to 2016 (North Carolina Department of Health 
and Human Services [NCDHHS], n.d.). In Wake County NC, 210 deaths per 100,000 population 
occurred due to drug-related complications, as reported by the data from 2012 to 2014 
(NCDHHS, n. d.). The Food and Drug Administration (FDA) of USA, approved Naloxone nasal 
spray as a life saving measure to reverse the effect of narcotic overdose in community settings by 
non -health care personnel (2019). An established family practice, located in Wake County, NC 
which renders medical services to adults, children, and families, served as the project partner for 
this Doctor of Nursing Practice (DNP) project. Narcotic medications are often prescribed for 
pain following the treatment guidelines. Naloxone co-prescription was not established in this 
practice. NCDHHS encourages the prescription of naloxone, an opioid antagonist, along with 
narcotics to prevent overdose-related deaths (NCDHHS, n.d.). 
Organizational Needs Statement 
Providers in the family practice are committed to serve the Wake County patient 
population with safe, high quality, and evidence-based care. The Site Champion for this DNP 
project is the director of the facility and he is inspired to ensure the safety of the patients who are 
receiving narcotic prescriptions for pain. In this practice, the providers prescribe narcotics to 
treat acute and chronic pain; however, they are not currently prescribing Naloxone nasal sprays 
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along with narcotics. Naloxone nasal sprays have proven to be useful in preventing opioid 
overdose complications and death (Parsons, 2019). NCDHHS has initiated a strategic plan for 
2017 to 2021 to address the opioid overdose issue. Naloxone prescribing, along with the 
narcotics, is one of the recommended strategies (NCDHHS,n.d.). The providers at this family 
practice recognize the importance and need to participate in the statewide efforts to reduce opioid 
overdose complications. 
 This family practice aims to increase providers’ and staff knowledge regarding the new 
Naloxone spray co-prescription practice policy and equip them with appropriate patient 
education materials. In NC, drug overdose deaths in 2018 were 20.4 for 100,000 people (North 
Carolina Institute of Medicine [NCIOM], 2020). According to ‘Healthy North Carolina 2030’, 
the target is to reduce deaths to at least 18 deaths per 100,000 people (NCIOM, 2020). The 
proposed DNP project may be an excellent tool for the family practice to participate in achieving 
the Healthy North Carolina 2030 goal. 
Problem Statement  
Increased narcotic overdose complications and deaths are becoming a global epidemic. In 
North Carolina, drug overdose deaths are increasing, requiring evidence-based prevention 
strategies (NCIOM, 2020). A family practice in Wake County recognizes a need for 
interventions to promote the safety of the patients who receive narcotic prescriptions for pain 
management. The facility was not providing any Naloxone prescriptions with narcotics. 
Purpose Statement 
     The purpose of the proposed DNP project was to implement an educational intervention to 
increase Naloxone spray co-prescription, at least by 5% in a two-month period. 
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Section II. Evidence 
Literature Review  
 A literature review was done using CINAHL and PubMed to understand the effectiveness 
and feasibility of Naloxone use in community settings. The keyword used for CINAHL was 
Naloxone nasal spray. The advanced search was chosen, full text and the English language were 
the limiters, and the articles published from April 2015 to April 2020 were selected. This search 
revealed 32 results. After reading the full texts, four research articles (n=4) were chosen for 
review as they were directly related to the Naloxone spray use in community settings. The search 
words used in PubMed were Naloxone nasal spray and opioid overdose. The filters used for this 
search were ‘published in the past five years’ and ‘English’. This search gave a result of 44 
articles. After reading the full text, ten directly related articles were chosen (n=10). The articles 
which were not directly relevant to the population were excluded such as the studies focused on 
the hospital or Emergency Department settings and for the specific populations such as use by 
Emergency Medical Technicians. The articles with lower than level- two evidence were also 
eliminated (n=2). Four articles were common in both the databases. Including PubMed and 
CINAHL, the final number of articles reviewed was 14. In addition to that, the North Carolina 
Naloxone Distribution Toolkit was reviewed to understand local resources and state standing 
orders. (North Carolina Division of Public Health- Injury and Violence Prevention Branch, 
2019).  See Appendix A and B for an overview of the literature search. 
Current State of Knowledge  
           Increased provider awareness and availability of easy to use Naloxone preparations, along 
with supporting state laws and policies, will encourage providers to prescribe more Naloxone for 
community use (Dunne, 2018). An open-label randomized five-way cross over Pharmacokinetics 
study including, 38 healthy volunteers, highly supports intranasal administration of concentrated 
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naloxone preparations for narcotic overdose (McDonald et al., 2018). Another pharmacokinetic 
study using an open-label randomized four-way cross over design, including twelve healthy 
volunteers, compared intranasal naloxone spray bioavailability with that of intravenous and 
sublingual preparations. This study reveals substantial bioavailability of intranasal preparation 
and recommends its use in emergencies in the community (Mundin et al., 2017). Lewis and 
colleagues (2017) conducted a systematic literature review regarding intranasal Naloxone use by 
non -medical personal in community settings. They recommend education and training, 
distribution of naloxone nasal sprays to high-risk population and families, reduction of barriers in 
prescribing, and elimination of legal recrimination fears as strategies to promote naloxone use for 
narcotics overdose emergencies in the community (Lewis et al., 2017). Skulberg and colleagues 
(2019) conducted an open, randomized four-way cross-over trial to understand the 
pharmacokinetics of intranasal Naloxone. The research concluded that intranasal Naloxone 
provides adequate systemic concentrations to treat opioid overdose compared with intramuscular 
Naloxone 0.8 mg (Skulberg et al., 2019). A prospective, single-site, open-label, randomized 
usability assessment by Eggleston and partners concluded that Naloxone is a safe and effective 
antidote for reducing opioid overdose deaths when it is distributed in the community (Eggleston 
et al., 2018). Ryan and Dunn (2018) conducted a systematic review regarding intranasal and 
injectable Naloxone forms for community use, which supported the practice of providing 
prescriptions for community use to reduce future risk of overdose in people who are receiving 
chronic opioid therapy for pain management. Another randomized controlled trial, to compare 
the pharmacokinetics of Naloxone using the FDA approved intranasal and intramuscular devices 
with the Improvised Nasal Naloxone Device (INND) reached the conclusion that FDA approved 
intranasal Naloxone is easier to use and reaches to the highest plasma concentrations compared 
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to intramuscular dose (Krieter et al., 2019). Strang and his colleagues (2016) conducted a three- 
stage analysis of candidate routes of administration of Naloxone. This study recommends the 
development and approval of non- injectable forms of Naloxone to facilitate community use 
(Strang, 2016). Vanky and team (2017) conducted a randomized control trial testing the 
pharmacokinetics of a single dose Naloxone spray in twenty healthy volunteers which revealed a 
faster absorption of intranasal Naloxone to maximum concentration compared to the injectable 
form (Vanky et al., 2017). An open randomized triple cross over trial by Tyllescar et al. (2017) 
also supports rapid systemic absorption and higher bioavailability of the nasal formulation 
compared to the other formulations. The findings from a prospective single-site open label 
randomized usability assessment assessing Naloxone administration by untrained community 
members suggests that administration by a nasal spray device was the easiest and the 
administration was conducted most rapidly compared to the intramuscular kit and improvised 
nasal atomizer kit (Eggleston et al., 2020). When Wright Quintin and team (2020) examined the 
effect of community education and distribution of Naloxone by pharmacists. The teaching was 
found to be effective, even though a smaller percentage of the public had to use the Naloxone in 
the two to four months follow up (Wright et al., 2020). Ida Tyllescar and team (2019) conducted 
a study regarding bystander use of Naloxone nasal spray for the opioid overdose. The authors 
reported that the bystander administered single-dose Naloxone spray in high concentrations can 
prevent deaths from opioid overdose (Tyllescar et al., 2019). See Appendix C for literature 
matrix. 
Current Approaches to Solving Population Problem(s) 
          While conducting the literature review, the author found multiple approaches to overcome 
the opioid overdose epidemic, such as prescription drug monitoring, nonpharmacological and 
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non-opioid pain management methods, and referrals to pain management specialists. Naloxone 
usage to prevent overdose complications and death was one of the strategies highly 
recommended (Tyllescar et al.,2019). Naloxone is available in many formulations such as 
intramuscular, intravenous, sublingual, and intranasal (Mundin et al., 2017).  The easiest and 
most effective administration method by the laypersons in the community is intranasal 
preparations as it is a needle-free approach (Lewis et al., 2017). The bioavailability of the 
intranasal preparation of Naloxone is much higher compared to the sublingual administration, 
which is another needle-free approach (Mundin et al., 2017). North Carolina State law allows 
medical providers to issue standing orders to dispense and distribute Naloxone to the population 
at higher risk for overdose (NCDHHS, n.d.).  
Evidence to Support the Intervention 
              The DNP project site is a family practice in North Carolina. North Carolina has a 
standing order to use naloxone nasal sprays in the community (NCDHHS,n.d.) The providers in 
the practice, have the legal authority to prescribe Naloxone nasal sprays for the population at risk 
for overdose (NCDHHS,n.d.). The tool kit from NCDHHS is easily available and extremely 
helpful for the patient and family education (NCDHHS,n.d.).The majority of patients attending 
this practice depend on Medicare/Medicaid or self -pay for their medications. Most insurances 
and Medicare cover Naloxone spray costs (Medicare, n.d.). Naloxone nasal sprays are available 
in local pharmacies. Intranasal naloxone kits are available in North Carolina local health 
departments for free of cost (NCDHHS,n.d.). Intranasal naloxone preparations are easy to use by 
non -medical community members and are effective in treating narcotic overdose emergencies in 
community settings (Lewis et al., 2017). Research suggests that people who received Naloxone 
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co-prescription from their primary care providers had rarer narcotic-related Emergency 
Department visits (Coffin et al., 2016). 
Evidence-Based Practice Framework 
Identification of the Framework 
      The IOWA Model of Evidence-Based Practice Implementation was used to execute the DNP 
project in practice (University of Iowa Hospitals & Clinics, 2020). The IOWA model includes 
multiple steps of the quality improvement process (University of Iowa Hospitals & Clinics, 
2020). These steps are problem identification, understanding the need or priority of this project 
to the organization, development of a team, gathering, analyzing and synthesizing the research 
related to the topic, implementing the change, and evaluating the results (University of Iowa 
Hospitals & Clinics, 2020). The IOWA model was selected because the chosen DNP project 
requires all the above- mentioned elements and steps to successfully implement the evidence -
based practice in the clinical setting. The proposed DNP project was based on an identified 
problem in the local community, the increased narcotic overdose deaths (NCDHHS, n. d.). 
Developing a team of motivated providers and other staff, providing education about the 
evidence- based research and state resources, promoted their cooperation.  
Ethical Consideration & Protection of Human Subjects  
 The proposed DNP project was an evidence-based practice implementation project 
designed to implement an educational intervention to promote co-prescription of Naloxone nasal 
spray with narcotics. The benefit of the project was offered to all the providers and staff who 
work at the organization. Participation in the educational intervention was voluntary and 
participants could withdraw from the project without any penalty. NCDHHS promotes Naloxone 
nasal spray use for Narcotic overdose in the community and North Carolina has a standing order 
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in place (NCDHHS, n.d.). The educational intervention helped to educate and prepare providers 
and staff at the family practice to implement the proposed evidence-based practice. The 
educational intervention was intended to promote quality and safety in the clinical setting, and it 
was not expected to cause any harm to any participants involved. A pre and post educational 
survey was done to evaluate the effect of education. Providers and the staff were not asked to 
reveal their identity while responding to the survey. The Project Leader prepared herself to 
observe ethical considerations during the proposed DNP project implementation by taking CITI 
modules through East Carolina University. The project site did not have a formal Institutional 
Review Board (IRB) process in place. The project was reviewed through the East Carolina 
University IRB process and deemed a Quality Improvement/Program Evaluation project, not 
requiring IRB review. 
Section III. Project Design 
Project Site and Population  
A family practice in Wake County NC was the project site for the proposed DNP project. 
It is a family practice, specializing in allergy and internal medicine. Providers in this practice 
provide comprehensive primary care, including medical services to adults, children, and families 
(Director of the family practice, personal communication, June 26, 2020). The organization 
provides services to people of all ages. The providers in this practice prescribe narcotics to treat 
patients with acute and chronic pain. Co-prescription of Naloxone nasal spray along with opioids 
to prevent narcotic overdose complications and deaths is one of the effective evidence -based 
interventions that was not established in this family practice. NCDHHS highly recommends this 
evidence-based practice to improve the safety of the patients who receive narcotics. The director 
of this facility identified the need to implement the intervention in this practice, to enhance 
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patient’s safety. When the Project Leader conducted a Strengths-Weaknesses-Opportunities-
Threats (SWOT) analysis, the strengths of this project in this site were motivated educator and 
project site champion, strong support from the management and the providers, and active 
involvement of the staff. The weaknesses were lack of electronic health record system, shortage 
of staff, and time-consuming processes. The opportunities recognized were the availability of 
research articles on this subject revealing effectiveness of Naloxone spray in preventing narcotic 
overdose related deaths, the variety of teaching materials on the subject, the North Carolina State 
standing order, and the NCDHHS website with a tool kit for providers to use for guidance. Some 
threats were recognized, such as the current COVID-19 pandemic situation which required social 
distancing and avoiding mass gathering for educational interventions.  
Description of the Setting 
 The family practice is in Wake County, NC. This practice provides primary health care 
services, including management of acute and chronic pain. The service accepts patients of all 
ages, cultures, socio-economic statuses, and variety of diagnoses. In this facility, the providers 
accept most insurance, Medicare, Medicaid, and self-pay. Providers in this practice provide care 
for about 60 patients per week, and about 8% of those patients receive narcotics for pain 
management. (Director of the family practice, personal communication, June 26, 2020). 
Description of the Population 
The target population for the DNP project was the providers and staff of the family 
practice. This practice has three advance practice providers, including the director. There are two 
Registered Nurses, eight Certified Medical Assistants, and five office staff. Two Nurse 
practitioner students receiving training in this facility were also present during the educational 
intervention. 
Project Team 
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 The project team consisted of three members. The author, who is a DNP student, was 
leader of the project. The Project Leader analyzed and synthesized the research related to the 
topic, implemented the educational intervention, and evaluated the results through weekly chart 
audits. The Site Champion was the director of the family practice. The Site Champion allowed 
space and time to conduct the educational intervention, supported the project and provided 
suggestions to overcome the barriers. A faculty member from the East Carolina University 
College of Nursing was the Project Coach for the project and provided mentorship during the 
duration of the project.  
Project Goals and Outcome Measures  
The project goal was to educate and equip providers and staff in the facility regarding the 
co-prescription of Naloxone spray with narcotics to prevent narcotic overdose emergencies and 
deaths. This evidence -based intervention is well established in other primary care settings and 
has wide variety of supportive research, as described in the literature review. The Project Leader 
conducted an educational intervention to encourage providers to follow the protocol as detailed 
by the NCDHHS. A pre and post educational survey was done to assess the effectiveness of the 
educational intervention. The chart audits helped to further evaluate the effect of the 
intervention. The IOWA Model of Evidence-Based Practice Implementation was used to execute 
the DNP project in practice (University of Iowa Hospitals & Clinics, 2020). A ‘run chart’ tool 
using bar chart was used as the tracking tool, to track the number of narcotic prescriptions and 
the Naloxone co-prescriptions. The author prepared herself, taking the Collaborative Educational 
Training Initiative (CITI) modules to understand the ethical considerations associated with 
conducting evidence-based project implementations. The author submitted the DNP project plan 
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to the East Carolina University’s Institutional Review Board (IRB) for approval before 
implementing it and obtained a waiver. 
Description of the Methods and Measurement 
The IOWA Model of Evidence-Based Practice Implementation was used to execute the 
proposed DNP project (University of Iowa Hospitals & Clinics, 2020).  This tool appeared to be 
the most appropriate tool for the proposed DNP project as the elements and steps of the IOWA 
model were precise and directly applicable in this project. The providers in the family practice 
were prescribing narcotics for pain management; however, they were not co-prescribing 
Naloxone along with the Narcotics to prevent opioid emergencies and death. The director of the 
facility identified this problem and wished to implement a project to motivate the providers. 
Developing a team of motivated providers and other staff and providing education about the 
evidence- based research and state level resources were used to promote their cooperation. The 
Project Leader analyzed and synthesized research data regarding the topic and documented it 
concisely using a literature matrix. See Appendix C for the literature matrix table. 
An educational intervention was planned and conducted. The educational intervention 
emphasized the significance of the drug overdose problem globally and domestically. The 
Project Leader reviewed the North Carolina State strategic plans to reduce overdose death rates 
and introduced the providers and staff to NCDHHS Naloxone Distribution Toolkit. Providers 
and staff were educated on the evidence-based research findings and explained why Naloxone 
nasal sprays are preferred over other Naloxone formulations for use in the community. Hard 
copies of Naloxone Distribution Toolkit were given to all participants and a copy was placed in a 
folder at the clinic workstation for reference. Providers and staff were educated on how to access 
the toolkit electronically. The Naloxone Distribution Toolkit contains the following information: 
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background and rationale about the drug overdose problems, Naloxone access law, dispensing 
and distribution standing orders, Naloxone frequently asked questions and answers, types of 
naloxone, comparing and contrasting Naloxone formulations, purchasing options, available 
Naloxone kits, sustainability planning, public awareness efforts, Naloxone administration 
instruction with pictures, NC’s Good Samaritan Law, and standing order templates for 
distribution and dispensing (North Carolina Division of Public Health- Injury and Violence 
Prevention Branch, 2019). 
The pre and post educational surveys helped to evaluate the effect of the educational 
program, See Appendix D for pre-educational survey and Appendix E for the post- educational 
survey forms. See Appendix F for the pre-educational survey results and Appendix G for the 
post-educational survey results. The educational intervention goal was to help providers and staff 
to understand the need for Naloxone co-prescriptions and motivate them. The outcomes of the 
proposed DNP project were measured by conducting weekly chart audits. The Project Leader 
conducted chart audits for a two- month (8 weeks) period. Weekly chart audits were used to 
track the progress of the project by counting the number of Naloxone sprays prescribed with 
narcotics. The project implementation tool was revised biweekly to meet the anticipated 
outcomes. 
Discussion of the Data Collection Process 
 A pre and post educational survey was done on the day of the educational event to 
understand the effectiveness of education. The pre and post educational questionnaire measured 
three aspects including motivation, awareness, and confidence concerning narcotic overdose and 
Naloxone nasal spray co-prescription. Chart audit was used to evaluate the impact of the 
intervention overtime. A weekly chart audit of all patients attending the clinic was done to see if 
any narcotics were prescribed. For the patient with narcotic prescriptions, co-prescription of 
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naloxone was verified. See Appendix H for the chart audit form. The data was placed in a bar 
chart format to evaluate trends, see Appendix I for the data tracking tool. The author contacted 
the prescribers frequently to assess the barriers and need for further education. 
Implementation Plan 
 Using the IOWA Model as the project framework, the project implementation was 
conducted from August 2020 to October 2020. After identifying the problem and need for 
intervention, the Project Leader, gathered and synthesized research information regarding 
Naloxone nasal spray co-prescriptions. The educational intervention was conducted to help the 
providers and staff to understand the need for Naloxone co-prescriptions and motivate them to 
prescribe it.  The staff were trained on patient education. The effect of the educational 
intervention was evaluated using pre and post educational questionnaires. Further evaluation was 
done conducting pre and post chart audit counting the narcotic and Naloxone prescriptions. The 
results were tracked weekly on a bar graph. The project leader continued follow up and when a 
drop in the number of Naloxone co- prescriptions were noted for two consecutive weeks, the 
barriers were explored. The process was revised biweekly using the IOWA Model of Evidence-
based Practice Implementation Framework. 
Timeline 
 The expected timeline for this project was three months from August 2020. The pre-data 
got collected for a four-week period, starting in August. The educational intervention was done 
on 08/27/2020, and the data collection for evaluation of the project was done for the following 
eight weeks, starting from 09/02/2020. The chart audits were done on 09/02/2020, 09/09/2020, 
09/16/2020, 09/23/2020, 09/30/2020, 10/07/2020, 10/14/2020 and 10/21/2020. Meetings with the 
Project Coach and Site Champion were done once in every two weeks to update on the progress 
of the project and obtain further suggestions for improvement. See Appendix J for the timeline. 
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Section IV. Results and Findings 
Results  
Counting the number of Naloxone nasal spray prescriptions against the total number of 
narcotic prescriptions provided the DNP project’s fundamental outcome measures. Prior to the 
intervention, the providers at the project site were not writing any Naloxone co-prescriptions.  
The educational intervention’s original goal was to introduce Naloxone nasal spray co-
prescription to the site and achieve at least a 5% compliance in writing the prescriptions in two 
months. The post-implementation data collection revealed that, out of 27 narcotic prescriptions 
during the eight weeks, 24 Naloxone prescriptions were written: representing 89% compliance in 
prescribing Naloxone along with the narcotics. Frequent reminders, constant follow up, and 
visual prompts served as the contributing factors for success. The Project Leader visited the site 
weekly; to collect the number of Narcotic and Naloxone co-prescriptions. 
Outcomes Data  
The outcomes data included the count of narcotic and Naloxone prescriptions in the 
project site, for a period of eight weeks. The process measurement was done following the 
IOWA Model and modifying the plan as required. The final step of the IOWA is evaluating the 
results of the intervention. Counting of the Naloxone spray prescriptions and narcotic 
prescriptions and tracking them helped in the project evaluation. The outcomes of the 
educational intervention were initially evaluated by providing pre and post-education 
questionnaire to learn if the education was effective enough to start the new evidence -based 
practice. A total of 20 staff participated in the educational intervention, of which 15% of 
participants were providers, 10% were nurse practitioner students, 10% were nurses, 40% were 
medical technicians, and 25 % were office staff. The pre and post educational questionnaire 
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measured motivation, awareness, and confidence, regarding Naloxone nasal spray co-
prescription. The post data revealed increased motivation, awareness, and confidence. Seventy 
(70%) of the attendees answered the knowledge question correctly at the beginning of the 
intervention, whereas 100% of the attendees answered it correctly at the end of the educational 
session. The pre-data collection and post-data collection of counting the narcotic prescriptions 
helped to further measure the educational intervention outcomes. The narcotic prescriptions and 
Naloxone prescriptions were counted weekly and the numbers were placed in a bar graph format 
to track the progress. The Project Leader recognized the need for further action when the number 
of Naloxone prescriptions were less than the number of narcotic prescriptions during the second 
and third weeks of post intervention. After talking with the providers and perceiving the need for 
reminders, the Project Leader introduced visual prompts in the examination rooms and on the 
prescription pads, which helped to remind the providers about Naloxone co-prescriptions. 
Discussion of Major Findings 
The initial analysis revealed the project exceed the preliminary goal for the project. The 
educational intervention was effective.  As elaborated in the Appendix G, the educational 
intervention helped to boost motivation, awareness, and confidence of the participants. The 
knowledge level regarding Naloxone was also measured using a knowledge question. One 
hundred (100 %) of the attendees were able to answer the knowledge question correctly at the 
end of the education.  The narcotic prescriptions and Naloxone prescriptions were counted 
weekly to ensure the education was helping with the implementation of the evidence -based 
practice.  The Project Leader tracked the data using a bar graph format for easily visualization 
and recognition of the results. During the first week of post intervention, the Naloxone 
prescriptions were the same numbers compared to the narcotic prescriptions. However, during 
the second and third weeks of post implementation, the Naloxone prescriptions were less than 
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the number of narcotic prescriptions. The Project Leader contacted the providers to understand 
the challenges and barriers associated with the decline in the co-prescriptions. A need for further 
action was recognized as the unintentional non-compliance was due to forgetfulness. The Project 
Leader met with the Site Champion and explored options for reminding the providers to 
prescribe Naloxone along with narcotics. Multiple options were considered to overcome this 
barrier, such as more site visits by the Project Leader, reeducation, and visual reminders. The 
visual triggers were identified as the best option secondary to feasibility, practicality, and cost-
effectiveness. Wall posters and stickers stating ‘Naloxone saves lives’, were placed throughout 
the office, which triggered the attention of the providers. The Project Leader reinforced the 
education during weekly site visits, to establish further compliance and to include more staff. 
The post interventional data for weeks four through eight indicated constant compliance in co-
prescribing Naloxone along with the narcotics. The count of narcotic prescriptions and Naloxone 
prescription numbers were the same signaling success of the intervention. To conclude, the 
compliance of prescribing Naloxone along with narcotic prescriptions, was found to be higher 
than the initial expectation as presented in the data collection tool. See Appendix I for the bar 
graph presentation of the data. 
Section V. Interpretation and Implications 
Cost -Benefit Analysis  
The project involved a substantial amount of time, effort, finances, and staff involvement. 
First and foremost, a dedicated leader should be available who can spend time researching the 
benefits versus costs of the project, its importance, current research data available, multiple 
forms of Naloxone and selecting the most appropriate form of Naloxone in the community. 
Further study on the availability of educational materials, and the individual state laws, are 
required. It is important to inquire about the availability of Naloxone in the local pharmacies. 
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The activities mentioned above require a significant amount of time, approximately 12 hours per 
week for about four months.  Financial expenses involved in this project include the costs for 
printing the educational materials and order sets, which was around $125 in total. The 
educational intervention was conducted in the staff breakroom in the form of a ‘lunch and learn’ 
format, which added expenses. The cost for the lunch was $288 including tax and delivery to the 
site and will depend on the number of participants. Costs for the wall posters and stickers used as 
visual reminders were the additional monetary expenses. The total cost was $150. Please see 
Appendix L for the detailed budget. 
The project did not bring any direct financial benefit to the site, but it will potentially 
improve the safety of the patient population who received narcotics treatment from this family 
practice. Naloxone is a life -saving measure in overdose emergencies. As the patients recognize 
the intervention’s advantage, it may eventually impact the trust and appreciation of the public 
towards the family practice. 
  A major barrier to implementation was the current COVID -19 pandemic situation. Due 
to the public gathering restrictions and safety precautions, the educational intervention was 
repeated multiple times during the day to avoid gathering as a large group in the conference 
room. This required additional time and undertaking from the Project Leader. The educational 
intervention was conducted several times to involve all staff, observing the social distancing 
guidelines and state laws for safety precautions. The Project Leader spent a total of six hours in 
the clinic to educate everybody in the clinic, instead of the initially anticipated two hours of 
educational intervention. 
Considering the significance of potentially reducing drug overdose deaths in the 
community, the project’s benefits far outweigh the costs and efforts involved. 
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Resource Management  
In addition to the financial resources, providers’ and staff’s time contributed to the 
success of the project. The Site Champion, the Project Leader, and several other staff members 
were involved in this project, including the  office staff who helped with the data collection, 
nursing staff who assisted with the patient education, and a volunteering leader/champion from 
the site to assist with the program’s sustainment. The aforementioned staff invested an immense 
amount of their time in getting involved in the successful implementation and sustainment of the 
project. The Site Champion spent 30 minutes for each meeting with the Project Leader which is a 
total of five hours. Office staff spent approximately 15 minutes at each visit to help the Project 
Leader with data collection, equaling 3 hours in total. Nursing staff spent an average of 5 
minutes to teach each patient about narcotic overdose and Naloxone. Twenty- four Naloxone 
prescriptions were written during the evaluation period, which required a total of 2 hours of 
patient education. A volunteering project champion spent 30 minutes with the Project Leader to 
get trained for the sustainment of the project in the setting. Printers were available at the site to 
print photocopies of NCDHHS patient education materials if required. This author did not use 
the printers from the site as the materials were already printed and prepared.  
If the site had resources such as a larger conference room, it could have been used for the 
educational intervention. The organization has a waiting area for the patients which can be used 
for further patient education and display of the patient education materials. The waiting area was 
not used during the current project, as the project’s main purpose was to educate staff and 
providers. Additional patient and community education will be the subsequential step of the 
project, which should be accomplished through the providers and staff. The Site Champion and 
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staff are aware of the benefits of using the waiting area for patient education and displaying the 
education material. 
Implications of the Findings 
 The findings of this DNP project indicate the ability to change practice and improve 
quality and safety of the patient care if a project is implemented with the support of evidence-
based research findings. The Project Leader should be dedicated and willing to spend time and 
energy for the project implementation and evaluation. It is equally important to develop a team 
who is motivated to work towards the goals. Constant follow up and timely interventions are the 
keystones for the success of any quality improvement projects. This particular project helped to 
introduce an evidence-based practice to a primary care setting aimed at avoiding narcotic 
overdose complications and deaths. This project is highly beneficial for the patient population 
who uses narcotics for pain control. It helps to uphold nursing values while ensuring safety and 
efficacy of care. 
Implications for Patients 
Naloxone nasal sprays are life saving measures for the patient population at risk for 
overdose-related complications. The patients and families need to be able to recognize overdose 
symptoms, have the medicine available, and know how to appropriately use the Naloxone in case 
of overdose incidents. As a result of this educational intervention, providers and staff are 
educating and empowering the patients. 
Implications for Nursing Practice 
  Safety and quality improvement are the essential components of nursing practice. This 
intervention upholds the nursing values by ensuring patients’ safety and educating the 
community to prevent complications and death. 
NALOXONE NASAL SPRAY COPRESCRIPTION 27 
 
Impact for Healthcare System(s) 
The health care system in the United States is striving to be more focused on prevention 
strategies. Narcotic overdoses and complications can be life-threatening and usually involve 
complicated care in the Emergency Department and intensive care units, which will be 
physically, financially, psychologically, and socially overwhelming to families, communities, 
and the health care system. Avoiding or limiting the complications can significantly help save 
lives, reduce financial costs, and ensure safety. 
Sustainability  
The organization is planning to sustain the project. A nurse practitioner from the family 
practice has volunteered to take the lead in sustaining the project and acting as a Project 
Champion. The Project Champion plans to sustain the project in the organization. The Project 
Champion plans to track the number of narcotic and Naloxone prescription numbers using the 
same tools as the Project Leader used. The family practice has committed to permitting the time 
necessary for the providers to write prescriptions and staff to educate patients. The practice has 
also committed maintaining a continuous supply of patient education materials and NCDHHS 
resources. The practice has a printer available and can afford the costs associated with printing 
the educational material. The Site Champion has the website addresses and sample copies. 
Dissemination Plan  
The current dissemination plans are to present the poster at the project site by the end of 
April 2021. The second plan for dissemination will be presenting to the East Carolina University 
College of Nursing in April 2021. Additionally, project will be presented in the NC Opioid 
Misuse and Overdose Prevention Summit, which will be held virtually in May 2021. Further 
dissemination plans include a podium presentation of this project at the Indian American Nurses 
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Association of North Carolina (IANA-NC) Nurses Week Celebration. The event date is not 
confirmed yet for the year of 2021. The abstract will be submitted to the event managing 
committee and continuous education committee. See Appendix M for the dissemination plan 
details. 
Section VI. Conclusion 
Limitations  
Current COVID-19 pandemic circumstance was a barrier in conducting the educational 
event in a classroom format. There were some limitations encountered during the 
implementation of the project. When the educational intervention was done in a smaller room, it 
had to be conducted multiple times throughout the day to follow the COVID19 restrictions, 
which limited the opportunities for classroom discussion among the attendees. Time constraint 
was another limitation in evaluating the project. If the project’s duration was longer, data could 
have collected from the patients to assess the amount patients/families who used Naloxone for 
narcotic overdose incidents. It may take years to collect detailed data, which is beyond the DNP 
student’s program expectation. 
Recommendations for Others  
For future students planning to conduct similar projects, the recommendation would be to 
focus on patient education. A project aimed at patient education can be conducted in a 
community level, state level, or national level. The students can collect and distribute patient 
education materials or demonstrate Naloxone nasal spray administration in a virtual conference 
or meeting. The presentation of the project at a conference as a podium or poster presentation has 
potential to captivate a large audience.  Future students could also focus on the comparison of 
different Naloxone forms in the community and the barriers and facilitators of using them. 
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Recommendations for Further Study  
Based on the current experience, this author advocates for more studies regarding the 
limitations and obstacles in prescribing Naloxone sprays in the community. As a future nurse 
practitioner, the author is enthusiastic to know, the number of Naloxone sprays used in the 
community by the trained lay individuals such as patients, family, or friends during an overdose 
crisis. The other recommended areas of research are to explore the options to involve community 
health care team, home health care services, and pharmacists in the distribution and education of 
Naloxone forms in the community. 
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Appendix B  
Literature Search from PubMed 
                                                           
  
Key Words used:  
'Naloxone Nasal 
Spray' and 'Opioid 
overdose'
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'English Language'
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found to be 
effective, even 
though a smaller 
percentage of the 
general public 
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Naloxone in the 
two to four 
months follow 
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Instruction: Please circle your best answer 
1. I feel motivated to educate the patients and families regarding narcotic overdose 
a. Strongly Agree 
b. Agree 
c. Neither agree nor disagree 
d. Disagree 
e. Strongly disagree 
2. I have awareness about opioid overdose complications and death 
        a. Strongly Agree 
        b. Agree 
       c. Neither agree nor disagree 
      d. Disagree 
      e. Strongly disagree 
3.I have the confidence to prescribe/teach patients regarding Naloxone nasal spray administration 
       a. Strongly Agree 
        b. Agree 
       c. Neither agree nor disagree 
      d. Disagree 
      e. Strongly disagree 
 
 
4. What are the signs of Narcotic overdose (choose the best answer) 
NALOXONE NASAL SPRAY COPRESCRIPTION 42 
 
a. Unresponsiveness 
b. Slow or shallow breathing 
c. Blue fingernails or lips 
d. All the above 
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Appendix E   
Post-Education Survey 
Instruction: Please circle your best answer 
1.  I feel motivated to educate the patients and families regarding narcotic overdose 
     a. Strongly Agree 
     b. Agree 
     c. Neither agree nor disagree 
     d. Disagree 
      e. Strongly disagree 
 
2. I have awareness about opioid overdose complications and death 
        a. Strongly Agree 
        b. Agree 
       c. Neither agree nor disagree 
      d. Disagree 
      e. Strongly disagree 
 
3.     I have the confidence to prescribe/teach patients regarding Naloxone nasal spray 
       a. Strongly Agree 
        b. Agree 
       c. Neither agree nor disagree 
      d. Disagree 
      e. Strongly disagree 
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4.     What are the signs of Narcotic overdose (choose the best answer) 
a. Unresponsiveness 
b. Slow or shallow breathing 
c. Blue fingernails or lips 
d. All the above  
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Appendix F 
Pre-Education Survey Results 
 
 Motivation Awareness Confidence 
Strongly Agree 10 8 3 
Agree 7 8 5 
Neither agree nor 
disagree 
3 4 5 
Disagree 0 0 7 
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Appendix G 
Post-Education Survey Results 
 Motivation Awareness Confidence 
Strongly Agree 14 18 15 
Agree 4 2 3 
Neither agree nor 
disagree 
2 0 2 
Disagree 0 0 0 
Strongly Disagree 0 0 0 
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Appendix H 
Chart Audit Form 
1. Any narcotics prescribed? 
2. Any Naloxone nasal sprays prescribed with narcotics? 
3. If Naloxone not prescribed with the narcotics, mention reason 
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Appendix I 



























Narcotic Vs Naloxone Prescriptions
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Appendix K 
Doctor of Nursing Practice Essentials 




g for Practice 
Competency – Analyzes and uses information 
to develop practice 
Competency -Integrates knowledge from 
humanities and science into context of nursing 
Competency -Translates research to improve 
practice 
Competency -Integrates research, theory, and 
practice to develop new approaches toward 
improved practice and outcomes 
During this DNP project, this 
author analyzed different data 
bases, evidence -based practice 
guidelines and state standing 
orders to translate the 
knowledge and implement the 
intervention to practice setting. 
Essential II 
Organization






Competency –Develops and evaluates practice 
based on science and integrates policy and 
humanities 
Competency –Assumes and ensures 
accountability for quality care and patient 
safety 
Competency -Demonstrates critical and 
reflective thinking 
Competency -Advocates for improved quality, 
access, and cost of health care; monitors costs 
and budgets 
Competency -Develops and implements 
innovations incorporating principles of change 
Competency - Effectively communicates 
practice knowledge in writing and orally to 
improve quality 
Competency - Develops and evaluates 
strategies to manage ethical dilemmas in patient 
care and within health care delivery systems 
 
During the DNP project, the 
author was able to develop and 
demonstrate leadership skills 
by leading the project, 
conducting meetings with 
multiple stakeholders involved 
in the process and advocating 
for patient’s safety and quality 
of care. The author was able to 
develop effective 
communication skills through 
academic writing and poster 
presentation to translate the 
knowledge to audience. The 
CITI modules and IRB process 
for the DNP project, increased 
the awareness about ethical 
dilemmas in health care 










Competency - Critically analyzes literature to 
determine best practices 
Competency - Implements evaluation 
processes to measure process and patient 
outcomes 
Competency - Designs and implements quality 
improvement strategies to promote safety, 
efficiency, and equitable quality care for 
patients 
Literature search was done 
using multiple databases and 
guidelines. The articles were 
read and critiqued and the 
levels of evidence were 
explored before adapting the 
practice for implementation. 
Successful implementation 
was conducted using the 
knowledge gained through 
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Competency - Applies knowledge to develop 
practice guidelines 
Competency - Uses informatics to identify, 
analyze, and predict best practice and patient 
outcomes 




articles. These findings will be 
disseminated to various sites 
through poster and podium 
presentation to increase the 
awareness of the health care 
workers and community. The 
current plans for 
disseminations include 
NCDHHS Opioid Misuse and 
Overdose Prevention Summit 
and Indian American Nurses 













on of Health 
Care 
Competency - Design/select and utilize 
software to analyze practice and consumer 
information systems that can improve the 
delivery & quality of care 
Competency - Analyze and operationalize 
patient care technologies 
Competency - Evaluate technology regarding 
ethics, efficiency and accuracy 
Competency - Evaluates systems of care using 
health information technologies 
 
The technology such as 
Microsoft word, EXCEL, 
Power point and various health 
care software applications and 
databases such as CINAHL 
and PubMed were used to 
plan, prepare, and evaluate the 
DNP project. The 
technological assistance will 
be continually used for future 
disseminations also. Privacy 
and confidentiality were 
maintained adequately by 
appropriate use and password 
protection. 






Competency- Analyzes health policy from the 
perspective of patients, nursing and other 
stakeholders 
Competency – Provides leadership in 
developing and implementing health policy 
Competency –Influences policymakers, 
formally and informally, in local and global 
settings 
Competency – Educates stakeholders 
regarding policy 
Competency – Advocates for nursing within 
the policy arena 
Competency- Participates in policy agendas 
that assist with finance, regulation and health 
care delivery 
The current policy and state 
laws and standing orders for 
Naloxone were analyzed and 
introduced to all stakeholders 
involved in the DNP project. 
The costs and benefits of the 
process in terms of finances, 
value of life and safety of 
patients were discussed during 
the educational intervention. 
Patient safety and quality were 
reinforced. 
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Competency – Advocates for equitable and 











Competency- Uses effective collaboration and 
communication to develop and implement 
practice, policy, standards of care, and 
scholarship 
Competency – Provide leadership to 
interprofessional care teams 
Competency – Consult intra-professionally, 
and inter-professionally to develop systems of 
care in complex settings 
During this DNP project the 
author was able to collaborate 
with the team members, site 
champion and the staff. Further 
interprofessional collaboration 
is being done for the 
dissemination of the project by 
contacting the community 









Competency- Integrates epidemiology, 
biostatistics, and data to facilitate individual 
and population health care delivery 
Competency – Synthesizes information & 
cultural competency to develop & use health 
promotion/disease prevention strategies to 
address gaps in care 
Competency – Evaluates and implements 
change strategies of models of health care 
delivery to improve quality and address 
diversity 
During this DNP project, the 
author used World Health 
Organization, Centers for 
Disease Control and North 
Carolina Department of Health 
and Human Services sites to 
obtain data regarding drug 
overdose and related deaths in 
the community. This data was 
helpful in assessing the need 
for intervention to improve 
population health and 
analyzing the educational 
needs of the targeted 
population. More study was 
done on the prevention 
strategies reading the 
evidence-based research 
articles. The information was 
synthesized and translated to 
practice to prevent 
complications and death in the 
patient population receiving 
narcotics for pain control. 
Based on the knowledge 
acquired and using IOWA 
model, an educational 
intervention was conducted 
aiming at improving the 
current situation. The results of 
the intervention were measured 
to evaluate the effectiveness. 






Competency- Melds diversity & cultural 
sensitivity to conduct systematic assessment of 
health parameters in varied settings 
Competency – Design, implement & evaluate 
nursing interventions to promote quality 
Competency – Develop & maintain patient 
relationships 
Competency –Demonstrate advanced clinical 
judgment and systematic thoughts to improve 
patient outcomes 
Competency – Mentor and support fellow 
nurses 
Competency- Provide support for individuals 
and systems experiencing change and 
transitions 
Competency –Use systems analysis to evaluate 
practice efficiency, care delivery, fiscal 
responsibility, ethical responsibility, and 
quality outcomes measures 
 
The DNP project was designed 
and implemented using the 
advanced clinical judgement to 
improve the safety of the 
patients who is receiving 
narcotic prescriptions. The 
outcomes were measured 
systematically to ensure the 
practice change. Through the 
DNP project intervention, the 
author was able successfully 
educate the providers, fellow 
nurses, and other team 
members regarding the 
Naloxone Nasal Spray co-
prescription to prevent narcotic 
overdose deaths. The privacy 
and cultural sensitivity were 
maintained while 
implementing an evaluating 
the project. Equal 
opportunities were given to all 
staff to participate in the 
project. 
 
                                                                         
  




Item Quantity Unit 
cost 
Total 
    
Project Supplies    
Pre and post Questionnaires  
(printing cost) 
50 $0.5 $25 
Brochures for patient education (printing cost) 100 $0.5 $50.00 
Pen 25 $1.03 $25.75 
Marker 2 $ 0.98 $1.96 
Educational Expenses    
Educational packet for providers and staff 
education 
25 $2.00 $50.00 
Flash Drive 1 $8.99 $8.99 
High Lighter 2 $1.50 $3.00 
Lunch expenses (Optional) 25 $10.00 $250.00 
Delivery expenses of food to the site 1 $20.00 $20.00 
Tax for the lunch 1 $18.12 $18.12 
Expenses for Visual Reminders     
Wall posters 5 $25 $125 
Stickers ‘Naloxone saves lives’  25 $1 $25 
Total   $602.82 
 
                                                  
  




No. Site Abstract 
Submission 
Presentation 
1 ECU CON  March 2021 April 2021 
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